Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASPEN-02: ALX148 plus azacitidine versus azacitidine in previously untreated higher-risk myelodysplastic syndrome
2021-000705-25Phase 2Completed
- Sponsor
- ALX Oncology
- Start
- Apr 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in myelodysplastic syndrome (MDS) comparing ALX148 + azacitidine with Azacitidine alone (2 arms). Primary endpoints: Complete response rate by investigator assessment and Complete response rate by independent central review. Started Apr 2021; status: completed.
02
Drugs
evorpaceptazacitidine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2021-000705-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000705-25.